{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:04:13Z","timestamp":1784347453386,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015285","name":"Hebei Province Medical Science Research Key Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017959","name":"Hebei Province Health Commission","doi-asserted-by":"publisher","award":["20260940"],"award-info":[{"award-number":["20260940"]}],"id":[{"id":"10.13039\/100017959","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.virusres.2026.199760","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T22:05:40Z","timestamp":1780869940000},"page":"199760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hepatitis B virus RNA levels and clinical characteristics of persistent viremia in HBsAg-positive patients undergoing nucleos(t)ide analog"],"prefix":"10.1016","volume":"370","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2240-3378","authenticated-orcid":false,"given":"Yuzhu","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virusres.2026.199760_bib0001","article-title":"Dynamics of serum pregenome RNA in chronic Hepatitis B patients receiving 96-month nucleos(t)ide analog therapy","volume":"9","author":"Tao","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.virusres.2026.199760_bib0002","series-title":"Global Hepatitis Report 2024: Action For Access in low- and middle-Income Countries","year":"2024"},{"issue":"2","key":"10.1016\/j.virusres.2026.199760_bib0003","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.virusres.2026.199760_bib0004","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"Fan","year":"2020","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.virusres.2026.199760_bib0005","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s11684-017-0590-z","article-title":"Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs","volume":"11","author":"Lu","year":"2017","journal-title":"Front. Med."},{"issue":"10","key":"10.1016\/j.virusres.2026.199760_bib0006","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00535-012-0737-2","article-title":"Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients","volume":"48","author":"Tsuge","year":"2013","journal-title":"J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.virusres.2026.199760_bib0007","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jhep.2016.09.028","article-title":"Serum HBV pgRNA as a clinical marker for cccDNA activity","volume":"66","author":"Giersch","year":"2017","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.virusres.2026.199760_bib0008","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2016.10.034","article-title":"Reply to: \"serum HBV pgRNA as a clinical marker for cccDNA activity\": consistent loss of serum HBV RNA might predict the \"para-functional cure\" of chronic hepatitis B","volume":"66","author":"Wang","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2026.199760_bib0009","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jhep.2017.08.021","article-title":"Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients","volume":"68","author":"Wang","year":"2018","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.virusres.2026.199760_bib0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New approaches to chronic Hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.virusres.2026.199760_bib0011","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections","volume":"75","author":"Martinez","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2026.199760_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda","year":"2020","journal-title":"Antiviral Res."},{"issue":"5","key":"10.1016\/j.virusres.2026.199760_bib0013","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/hep.32479","article-title":"Circulating HBV RNA: from biology to clinical applications","volume":"76","author":"Deng","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.virusres.2026.199760_bib0014","article-title":"Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment","volume":"13","author":"Li","year":"2023","journal-title":"Front. Cell Infect. Microbiol."},{"issue":"4","key":"10.1016\/j.virusres.2026.199760_bib0015","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2011.06.036","article-title":"Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma","volume":"141","author":"Chen","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virusres.2026.199760_bib0016","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.3390\/jcm10235617","article-title":"Quantitative HBsAg versus HBV DNA in predicting significant Hepatitis activity of HBeAg-positive chronic HBV infection","volume":"10","author":"Zhang","year":"2021","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.virusres.2026.199760_bib0017","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.cgh.2012.03.016","article-title":"High rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"10","author":"Pan","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"9865","key":"10.1016\/j.virusres.2026.199760_bib0018","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.virusres.2026.199760_bib0019","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4103\/sjg.sjg_16_24","article-title":"Elevated Hepatitis B virus RNA levels in hepatocellular carcinoma patients compared to cirrhotic individuals: a propensity score matched analysis","volume":"30","author":"Wang","year":"2024","journal-title":"Saudi. J. Gastroenterol."},{"issue":"9663","key":"10.1016\/j.virusres.2026.199760_bib0020","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.virusres.2026.199760_bib0021","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.cell.2015.03.005","article-title":"Immunosurveillance of the liver by intravascular effector CD8(+) T cells","volume":"161","author":"Guidotti","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.virusres.2026.199760_bib0022","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.jhep.2016.10.002","article-title":"T cell regulation in HBV-related chronic liver disease","volume":"66","author":"Ferrari","year":"2017","journal-title":"J. Hepatol."},{"issue":"40","key":"10.1016\/j.virusres.2026.199760_bib0023","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027433","article-title":"Analysis of serum hepatitis B virus RNA levels among HBsAg and HBsAb copositive patients and its correlation with HBV DNA","volume":"100","author":"Xiang","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.virusres.2026.199760_bib0024","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12967-017-1214-8","article-title":"The spleen in liver cirrhosis: revisiting an old enemy with novel targets","volume":"15","author":"Li","year":"2017","journal-title":"J. Transl. Med."},{"issue":"9","key":"10.1016\/j.virusres.2026.199760_bib0025","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/jvh.12908","article-title":"Natural history of serum HBV-RNA in chronic HBV infection","volume":"25","author":"Wang","year":"2018","journal-title":"J. Viral. Hepat."},{"issue":"2","key":"10.1016\/j.virusres.2026.199760_bib0026","first-page":"104","article-title":"Evaluation of pregenomic HBV RNA in HBeAg-negative patients","volume":"45","author":"Roncarati","year":"2022","journal-title":"New. Microbiol."},{"issue":"3","key":"10.1016\/j.virusres.2026.199760_bib0027","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/hep.29872","article-title":"Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment","volume":"68","author":"van Campenhout","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.virusres.2026.199760_bib0028","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","author":"Wang","year":"2016","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.virusres.2026.199760_bib0029","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/infdis\/jiv397","article-title":"Hepatitis B Virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues","volume":"213","author":"Jansen","year":"2016","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.virusres.2026.199760_bib0030","first-page":"257","article-title":"Clinical study of hepatitis B virus RNA in chronic hepatitis B patients with different HBeAg status","volume":"33","author":"Zhang","year":"2023","journal-title":"Chinese Journal of Health Laboratory Technology"},{"issue":"409","key":"10.1016\/j.virusres.2026.199760_bib0031","doi-asserted-by":"crossref","first-page":"eaan0241","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"18","key":"10.1016\/j.virusres.2026.199760_bib0032","doi-asserted-by":"crossref","DOI":"10.1172\/JCI161818","article-title":"Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment","volume":"132","author":"Grudda","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.virusres.2026.199760_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2024.101144","article-title":"Hepatitis B virus enhancer 1 activates preS1 and preS2 promoters of integrated HBV DNA impairing HBsAg secretion","volume":"6","author":"Gu","year":"2024","journal-title":"JHEP Reports"}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170226000791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170226000791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:53:21Z","timestamp":1784346801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170226000791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"alternative-id":["S0168170226000791"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2026.199760","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B virus RNA levels and clinical characteristics of persistent viremia in HBsAg-positive patients undergoing nucleos(t)ide analog","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2026.199760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"199760"}}